Researcher
dr. Fréderique de Graaf
Curriculum Vitae
I completed my Master's studies at Utrecht University, the Netherlands, where I received my first formal research training in the laboratory of Prof. Meyaard at the Department of Translational Immunology, University Medical Center Utrecht. I subsequently conducted a second research internship in the laboratory of Prof. Pezacki at the Department of Biochemistry, University of Ottawa, Canada, and graduated cum laude.
I obtained my PhD degree at Erasmus Medical Center, Rotterdam, under the supervision of Prof. Casper van Eijck and Prof. Ron Fouchier. My doctoral research focused on avian paramyxoviruses and their application in oncolytic viro-immunotherapy. During this period, I developed and characterized novel viral vectors aimed at improving both the environmental safety and therapeutic efficacy of oncolytic viruses.
From 2020 to 2023, I worked as a Scientist at Immunetune, in close collaboration with Leiden University Medical Center (LUMC), where I contributed to the development of synthetic linear DNA as a novel platform for personalized neoantigen vaccines. In 2023, I joined LUMC to further advance the development of immune-modulatory cancer therapies in the group of Prof. Ramon Arens, with a particular focus on immunometabolism. In 2026, I expanded this research line through a joint appointment in the group of Prof. Bart Everts, investigating the impact of aging on immunometabolism within a clinical study setting.
Publications
-
Metabolic profiling of antigen-specific CD8+ T cells by spectral flow cytometry.
Mülling N, de Graaf JF, et al., (2025).
Cell Reports Methods. DOI: 10.1016/j.crmeth.2025.101185 – IF: 6.7 – Citations: 4
-
Cell-derived Newcastle Disease Virus variant with two amino acid substitutions near cleavage site of shows favorable traits as oncolytic virus.
Huberts M, de Graaf JF, et al., (2025)
Molecular Therapy Oncology. in print – IF: 5.4 – Citations: 3
-
Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer.
de Graaf JF, et al., (2024)
Molecular Therapy Oncology. DOI10.1016/j.omton.2024.200835 – IF:5.4 – Citations: 13
Groups:
Cellular Immunometabolism
